Adoptive T-cell immunotherapy for patients with Epstein-Barr virus-associated nasopharyngeal carcinoma



This study is evaluating the effect of using T cell immunotherapy following standard chemotherapy for the treatment of nasopharyngeal cancer (NPC).


Participation involves

All participants in this study will receive standard chemotherapy with gemcitabine and cisplatin according to their clinician’s standard clinical care. Following this, they will undergo the experimental immunotherapy. This involves infusing Epstein-Barr virus (EBV) specific T-cells intravenously (i.e. directly into the vein) up to 6 times, at fortnightly intervals.

Participants will be regularly assessed for up to 38 weeks in order to evaluate their response to treatment, and the safety and tolerability of treatment.


Eligibility criteria

You may be eligible to join this study if you are aged 18 years or above and have been diagnosed with metastatic nasopharyngeal cancer and your clinician is planning to treat you with standard chemotherapy.

More eligibility criteria can be viewed at


Description of Trial

A clinical trial of adoptive T-cell immunotherapy for patients with Epstein-Barr virus-associated nasopharyngeal carcinoma.

QIMR-HREC approval reference: P1486

Open Date: 2013

Recruitment status: CLOSED





Coordinators: Dr Michelle Neller / Professor Rajiv Khanna

T: 07 3362 0412


A: QIMR Berghofer Medical Research Institute,

Locked Bag 2000, Royal Brisbane Hospital

Herston, QLD, 4029, AUSTRALIA

Participate Now